Geron Corporation Stockholders Encouraged to Contact Securities Law Firm about
DALLAS, March 24, 2014
DALLAS, March 24, 2014 /PRNewswire/ -- Securities lawyers at Deans & Lyons
announce an investigation of the board of Geron Corporation (NASDAQ: GERN).
Concerned GERN investors who purchased between June 16, 2013 and March 11,
2014 are encouraged to contact securities attorney Hamilton Lindley by
"After the March 12, 2014 announcement that the FDA put Geron's
Investigational New Drug application for imetelstat on full clinical hold,
stock plummeted more than 60%," said securities lawyer Hamilton Lindley. "Our
potential shareholder lawsuit will seek to ensure that all relevant
information is disclosed to Geron Corporation shareholders."
Deans & Lyons has significant experience representing shareholders in
securities lawsuits nationwide. GERN stockholders – or anyone with knowledge
about this situation – should contact lawyer Hamilton Lindley at
email@example.com or 877-819-8033 with questions or concerns.
DEANS & LYONS LLP
325 North Saint Paul Street, Suite 1500
Dallas, TX 75201
SOURCE Deans & Lyons LLP
Press spacebar to pause and continue. Press esc to stop.